Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey
| Autor: | Shogo Kin, Takashi Oishi, Hideki Tokunaga, Tomoe Tando, Yuji Yoshida, Nobuo Yaegashi, Satoshige Wagatsuma, Toru Sugiyama, Toshihiko Matsui, Tadahiro Shoji, Hidekazu Nishigori, Takeo Otsuki, Takafumi Watanabe, Tadashi Hayasaka, Satoko Kagabu, Noriaki Imai, Yoshihito Yokoyama, Fumiaki Takahashi, Hiroaki Shimokawa, Hiroki Yamamoto, Tsuyoshi Honda, Kazuyo Sato, Hidekazu Yamada, Kosuke Yoshinaga, Hirokazu Sato, Yoh Watanabe |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
Leiomyosarcoma medicine.medical_specialty Combination therapy Docetaxel Malignancy Deoxycytidine Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Japan Surgical oncology Antineoplastic Combined Chemotherapy Protocols Humans Medicine 030212 general & internal medicine Stage (cooking) Aged Retrospective Studies Performance status business.industry Retrospective cohort study Hematology General Medicine Middle Aged Prognosis medicine.disease Combined Modality Therapy Health Surveys Gemcitabine Surgery Clinical trial Oncology 030220 oncology & carcinogenesis Uterine Neoplasms Lymph Node Excision Female Taxoids Neoplasm Recurrence Local business medicine.drug |
| Zdroj: | International Journal of Clinical Oncology. 22:541-547 |
| ISSN: | 1437-7772 1341-9625 |
| DOI: | 10.1007/s10147-017-1097-y |
| Popis: | To prepare for a future clinical trial for improving the long-term prognosis of patients with uterine leiomyosarcoma (ULMS), we conducted a multi-institutional survey in the Tohoku region of Japan. We conducted a retrospective cohort study between 2011 and 2014 in member institutions of the Tohoku Translational Research Center Development Network. A total of 53 patients with ULMS were registered in 31 institutions for the present survey. The median patient age was 56 years, 67.9% of the patients were postmenopausal, 88.7% had a performance status of 0 or 1, and only 6 patients (11.3%) showed preoperative evidence of malignancy. Although retroperitoneal lymphadenectomy was performed in only 26.4% of patients, 64.2% patients were identified as having FIGO stage 1 disease; 73.6% were eligible to undergo complete surgery. Among 36 patients who were treated with postoperative chemotherapy, 28 (77.8%) received docetaxel and gemcitabine combination therapy. The most frequent recurrence site was the lungs, and the median progression-free survival of all enrolled patients was 11.7 months. However, the median progression-free survival and the median overall survival in patients with stages III and IV disease were 3.4 and 11.4 months, respectively. Although ULMS was associated with a high rate of complete or optimal surgery, the long-term prognosis was poor. Effective postoperative therapy should be developed to improve the long-term prognosis of patients with ULMS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink